{"prompt": "['considers the event to be reasonably related to the study treatment or study participation, the', 'investigator must promptly notify Merkk.', '7.2.1 Definition of an Overdose for This Protocol and Reporting of Overdose to the', 'Principal Investigator and to Merck', 'For purposes of this study, an overdose of pembrolizumab will be defined as any dose of', '1,000 mg or greater (>5 times the indicated dose). No specific information is available on', 'the treatment of overdose of pembrolizumab. In the event of overdose, the participant should', 'be observed closely for signs of toxicity. Appropriate supportive treatment should be', 'provided if clinically indicated.', 'Due to the high plasma protein binding, lenvatinib is not expected to be dialyzable. Death', 'due to multiorgan dysfunction occurred in a patient who received a single dose of lenvatinib', '120mg orally.', 'If an adverse event(s) is associated with (\"results from\") the overdose of a Merk product,', 'the adverse event(s) is reported as a serious adverse event, even if no other seriousness', 'criteria are met.', \"If a dose of Merck's product meeting the protocol definition of overdose is taken without any\", 'associated clinical symptoms or abnormal laboratory results, the overdose is reported as a', 'non-serious Event of Clinical Interest (ECI), using the terminology \"accidental or intentional', 'overdose without adverse effect.\"', 'All reports of overdose with and without an adverse event must be reported within 24 hours', 'to the principal investigator (PI) and within 2 working days hours to Merk Global Safety.', '(Attn: Worldwide Product Safety; FAX 215-661-6229)', '7.2.2 Reporting of Pregnancy and Lactation to the Principal Investigator and to', 'Merk', 'Although pregnancy and infant exposure during breast feeding are not considered adverse', 'events, it is the responsibility of investigators or their designees to report any pregnancy or', 'lactation in a participant (spontaneously reported to them) that occurs during the study.', 'Pregnancies and infant exposures during breastfeeding that occur after the consent form is', 'signed but before treatment allocation/randomization must be reported by the investigator if', 'they cause the participant to be excluded from the trial, or are the result of a protocol-', 'specified intervention, including but not limited to washout or discontinuation of usual', 'therapy, diet, placebo treatment or a procedure.', 'Pregnancies and infant exposures during breastfeeding that occur from the time of treatment', \"allocation/randomization through 120 days following cessation of Supporter's product, or 30\", 'days following cessation of treatment if the participant initiates new anticancer therapy,', 'whichever is earlier, must be reported by the investigator. All reported pregnancies must be', 'followed to the completion/termination of the pregnancy. Pregnancy outcomes of', 'spontaneous abortion, missed abortion, benign hydatidiform mole, blighted ovum, fetal', '56']['death, intrauterine death, miscarriage and stillbirth must be reported as serious events', '(Important Medical Events). If the pregnancy continues to term, the outcome (health of', 'infant) must also be reported.', 'Such events must be reported within 24 hours to the PI and within 2 working days to Merk', 'Global Safety. (Attn: Worldwide Product Safety; FAX 215-661-6229)', '7.2.3 Immediate Reporting of Adverse Events to the Principal Investigator and to', 'Merck', '7.2.3.1 Serious Adverse Events', 'An adverse event (AE) or suspected adverse reaction is considered \"serious\" if, in the view of', 'either the investigator or sponsor, it results in any of the following outcomes:', 'Death', 'Life-threatening adverse event', 'Inpatient hospitalization or prolongation of existing hospitalization', 'A persistent or significant incapacity or substantial disruption of the ability to conduct', 'normal life functions, or a congenital anomaly/birth defect.', 'Important medical events that may not result in death, be life-threatening, or require', 'hospitalization may be considered serious when, based upon appropriate medical judgment,', 'they may jeopardize the participant and may require medical or surgical intervention to', 'prevent one of the outcomes listed in this definition. (Examples of such medical events', 'include allergic bronchospasm requiring intensive treatment in an emergency room or at', 'home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the', 'development of drug dependency or drug abuse).', 'For the time period beginning when the consent form is signed until treatment', 'allocation/randomization, any serious adverse event, or follow up to a serious adverse event,', 'including death due to any cause that occurs to any participant must be:', 'submitted on a Winship SAE form and assessed by PI in order to determine', 'reporting criteria to regulatory authorities', 'reported within 2 working days to Merk Global Safety if it causes the participant to', 'be excluded from the trial, or is the result of a protocol-specified intervention,', 'including but not limited to washout or discontinuation of usual therapy, diet,', 'placebo treatment or a procedure.', 'For the time period beginning at treatment allocation through 90 days following cessation of', 'treatment, or 30 days following cessation of treatment if the subject initiates new anticancer', 'therapy, whichever is earlier, any serious adverse event, or follow up to a serious adverse', 'event, including death due to any cause whether or not related to the study drug, must be:', 'submitted on a Winship SAE form and assessed by PI in order to determine', 'reporting criteria to regulatory authorities,', 'reported within 2 working days to Merk Global Safety', '57']\n\n###\n\n", "completion": "END"}